C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 115 filers reported holding C4 THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $91,176 | +76.4% | 19,735 | +19.9% | 0.00% | – |
| Q1 2023 | $51,678 | -46.8% | 16,458 | 0.0% | 0.00% | – |
| Q4 2022 | $97,102 | -32.7% | 16,458 | 0.0% | 0.00% | – |
| Q3 2022 | $144,337 | +26.6% | 16,458 | +8.6% | 0.00% | – |
| Q2 2022 | $114,000 | -69.0% | 15,161 | 0.0% | 0.00% | -100.0% |
| Q1 2022 | $368,000 | -24.6% | 15,161 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $488,000 | -26.5% | 15,161 | +2.0% | 0.00% | 0.0% |
| Q3 2021 | $664,000 | +29.4% | 14,864 | +9.6% | 0.00% | 0.0% |
| Q2 2021 | $513,000 | – | 13,560 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 6,880,527 | $31,788,035 | 11.47% |
| Soleus Capital Management, L.P. | 4,051,996 | $18,720,222 | 1.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,442,841 | $6,665,925 | 1.57% |
| COMMODORE CAPITAL LP | 3,410,384 | $15,755,974 | 1.08% |
| TCG Crossover Management, LLC | 1,276,574 | $5,897,772 | 0.62% |
| Bain Capital Life Sciences Investors, LLC | 1,111,910 | $5,137,024 | 0.56% |
| RA Capital Management | 4,878,000 | $22,536,360 | 0.30% |
| Atom Investors LP | 332,620 | $1,536,704 | 0.15% |
| Orbimed Advisors | 1,513,058 | $6,990,328 | 0.14% |
| WASATCH ADVISORS LP | 4,847,150 | $22,393,833 | 0.12% |